Medicare (CMS) June 24th 2018 Local Coverage Determination (LCD) Updates

Centers for Medicare & Medicaid Services (CMS) Local Coverage Determination (LCD) Updates »

June 24th 2018 LCD Updates:

• L33418              Assays for Vitamins and Metabolic Function
• A52370             Bevacizumab – Related to LCD L33394
• L33270              Bisphosphonates (Intravenous [IV]) and Monoclonal Antibodies in the Treatment of Osteoporosis and Their Other Indications
• L35490              Category III Codes
• L33392              Category III CPT® Codes
• L34093              Chemotherapy and Biologicals
• L34052 (retired) Chest X-Ray Policy
• L34097 (retired) Chest X-Ray Policy
• A54517 (retired) DRAFT Lower Limb Prostheses – Policy Article – Effective XXXX XXXX
• L34633              Erythropoiesis Stimulating Agents (ESAs)
• L34892              Facet Joint Interventions for Pain Management
• A56019             High Intensity Focused Ultrasound (HIFU) in the Treatment of Recurrent Prostate Cancer
• A52842             Local Coverage Determination (LCD) Reconsideration Process – Medical Policy Article
• L37665              MolDX: AlloSure Donor-Derived Cell-Free DNA Test
• A55145             MolDX: BCKDHB Gene Test Coding and Billing Guidelines
• A55148             MolDX: BLM Gene Analysis Coding and Billing Guidelines
• A55146             MolDX: BluePrint® Coding and Billing Guidelines
• A55970             MolDX: CDH1 Genetic Testing Billing and Coding Guidelines
• A55971             MolDX: CDH1 Genetic Testing Billing and Coding Guidelines
• A55622             MolDX: CDH1 Genetic Testing Coding and Billing Guidelines
• A55156             MolDX: CFTR Gene Analysis Coding and Billing Guidelines
• A55157             MolDX: CHD7 Gene Analysis Coding and Billing Guidelines
• L37210              MolDX: Decision Dx-UM (Uveal Melanoma)
• L37663              MolDX: EndoPredict® Breast Cancer Gene Expression Test
• A56020             MolDX: FDA Approved CLL Companion Diagnostic Test Coding and Billing Guidelines
• A55161             MolDX: FDA-Approved BRAF Tests
• A55162             MolDX: FDA-Approved KRAS Tests
• L35633              MolDX: GeneSight® Assay for Refractory Depression
• L36323              MolDX: GeneSight® Assay for Refractory Depression
• L36325              MolDX: GeneSight® Assay for Refractory Depression
• A55190             MolDX: Mitochondrial Nuclear Gene Tests Coding and Billing Guidelines
• A55292             MolDX: myPap™ Billing and Coding Guidelines
• A55293             MolDX: myPap™ Billing and Coding Guidelines
• A55195             MolDX: myPap™ Coding and Billing Guidelines
• A55224             MolDX: Myriad’s BRACAnalysis CDx®™ Coding and Billing Guidelines
• L37199              MolDX: Oncotype DX® Breast Cancer for DCIS (Genomic Health™)
• L37667              MolDX: Oncotype DX® Genomic Prostate Score for Men with Favorable Intermediate Risk Prostate Cancer
• L37195              MolDX: Percepta© Bronchial Genomic Classifier
• L37226              MolDX: Prolaris™ Prostate Cancer Genomic Assay for Men with Favorable Intermediate Risk Disease
• L37216              MolDX: Xpresys Lung
• L35049              Monitored Anesthesia Care
• L34859              Nerve Conduction Studies and Electromyography
• A56035             Nerve conduction studies and electromyography revision to the Part A and Part B LCD
• L34555              Non-Covered Category III CPT Codes
• A56043             Non-emergency ground ambulance services retired Part A and Part B LCD
• L34552              Outpatient Observation Bed/Room Services
• A52725             Peripheral Nerve Blocks Non-covered for the Treatment of Diabetic Peripheral Neuropathic Pain
• A56034             Peripheral Nerve Blocks Non-covered for the Treatment of Diabetic Peripheral Neuropathic Pain
• L33972              Psychiatric Partial Hospitalization Program
• A56036             Psychiatric partial hospitalization program revision to the Part A LCD
• A56037             Psychiatric Partial Hospitalization Program Coding Guidelines
• L34317 (retired) Radiologic Examination, Chest
• A56010             Response to Comments: Facet Joint Interventions for Pain Management
• A56022             Response to Comments: MolDX: AlloSure Donor-Derived Cell-Free DNA Test (DL37665).
• A56021             Response to Comments: MolDX: EndoPredict® Breast Cancer Gene Expression Test (DL37663).
• A56023             Response to Comments: MolDX: Oncotype DX® Genomic Prostate Score for Men with Favorable Intermediate Risk Prostate Cancer (DL37667).
• L33751              Scanning Computerized Ophthalmic Diagnostic Imaging (SCODI)
• A56031             Scanning computerized ophthalmic diagnostic imaging (SCODI) revision to the Part A and Part B LCD
• A53066             Self-Administered Drug Exclusion List
• A52933 (retired) TENS Clarification
• L34641              Transcranial Magnetic Stimulation (TMS)
• L34536              Treatment of Varicose Veins of the Lower Extremities
• L33454              Varicose Veins of the Lower Extremities
• L34537              Vestibular Function Testing

Centers for Medicare & Medicaid Services (CMS) Local Coverage Determination (LCD) Updates »

Policy Alerts monitors Commercial and Medicare medical policies for changes. While medical Insurance carriers typically update medical policies annually, there are many reasons why they might review or update a policy. When reviews occur out of cycle they often go unnoticed. Policy Alerts keeps you updated when Payers make coverage changes to medical policies affecting your business.

Policy Alerts continuously monitors Commercial and Medicare Payer coverage information to keep you up-to-date on medical Insurance decisions in real-time. When changes occur, instant email alerts are delivered to your inbox. Clients have access to detailed coverage reports and medical policies through the interactive Policy Alerts Dashboard portal. Save time each month and keep focused on important Payer medical policy reviews and coverage decisions affecting your business!

Policy Alerts takes a client-focused hands-on approach and is constantly working to provide our customers with helpful insights and actionable analytics. We understand what our clients need and are dedicated to providing timely, accurate, and always up-to-date reports.

Health economic and reimbursement information provided by Policy Alerts is gathered from third-party sources and is subject to change without notice as a result of complex and frequently changing laws, regulations, rules and policies. All product and company names are trademarks™ or registered® trademarks of their respective holders. Use of them does not imply any affiliation with or endorsement by them. This information is presented for illustrative purposes only and does not constitute reimbursement or legal advice.